Former President and Chief Executive Officer · Mersana Therapeutics, Inc. (MRSN)

Anna Protopapas

A named executive officer of Mersana Therapeutics in every fiscal year CompBrief holds from FY2018 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$4,450,009

Salary $448,333Stock awards $757,500

FY2022: $2,846,107

1st of 7 named executive officers at Mersana Therapeutics by FY2023 total.

7 named officers on file for Mersana Therapeutics, FY2023

Anna Protopapas’s pay file — $29

  • 6 fiscal years of pay, line by line
  • 13 equity grants, each cited to its filing
  • MRSN’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Mersana Therapeutics’s whole pay program stands against its peers

  • Mersana Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on MRSN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Anna Protopapas’s full pay file as a PDF — free

More than this page: up to 10 years of Anna’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Anna Protopapas compensation by year

Mersana Therapeutics Summary Compensation Table · all 6 fiscal years held
In US dollars, as Mersana Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2020FY2021FY2022FY2023
Salary$515,000$533,000$550,000$569,250$605,000$448,333
Bonus$0$0$0$0$0$0
Stock awards$0$400,000$436,331$1,792,650$420,760$757,500
Option awards$1,879,900$506,645$1,220,079$5,632,504$1,377,747$3,019,207
Non-equity incentive$206,000$293,150$324,500$276,086$435,600$0
Pension and deferred compensation$0$0$0$0$0$0
All other$6,000$7,000$7,000$7,000$7,000$224,969
Total$2,606,900$1,739,795$2,537,911$8,277,490$2,846,107$4,450,009

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Mersana Therapeutics, Inc. DEF 14A filed April 26, 2024, accession 0001104659-24-052235, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Mersana Therapeutics, Inc. filed document, accession 0001104659-24-052235. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

$2.6M
$1.7M
$2.5M
$8.3M
$2.8M
$4.5M
FY18
FY19
FY20
FY21
FY22
FY23
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU125,000$290,000—
RSU50,250$116,580—
RSU42,500$98,600—
RSU17,708$41,083—
RSU16,643$38,612—
Option169,566—$6.28
Option19,922—$6.16
Option457,031—$6.06
Option16,643—$1.32

Per the Outstanding Equity Awards at Fiscal Year-End table in Mersana Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

30 Form 4 lines since the FY2023 proxy (filed April 26, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-01-06Disposition to the issuer derivative—480—0
2026-01-06Disposition to the issuer derivative—542—0
2026-01-06Disposition to the issuer derivative—2,460—0
2026-01-06Disposition to the issuer derivative—2,500—0
2026-01-06Disposition to the issuer derivative—11,761—0
2026-01-06Disposition to the issuer derivative—7,519—0
2026-01-06U—2,890—0
2026-01-06Disposition to the issuer derivative—8,137—0

The 8 most recent of 30 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Change-in-control & termination

estimated payments Mersana Therapeutics discloses, by trigger · FY2023
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Retirement$135,164$0$0$430,071
Change in control, no termination$0$77,224$0$77,224

Per the Potential Payments Upon Termination or Change in Control table in Mersana Therapeutics, Inc.'s FY2023 proxy. Estimates as the company printed them; a dash means it printed no figure.

Mersana Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Anna Protopapas · this pageFormer President and Chief Executive Officer$4,450,009
Martin HuberPresident and Chief Executive Officer$2,601,249
Arvin YangFormer Senior Vice President, Chief Medical Officer$1,912,352
Brian DeSchuytnerSenior Vice President, Chief Operating Officer and Chief Financial Officer$1,738,215
Timothy LowingerSenior Vice President, Chief Science and Technology Officer$1,689,068
Alejandra CarvajalSenior Vice President, Chief Legal Officer$1,613,231
Mohan BalaSenior Vice President, Chief Development Officer$1,581,334

Board service

Mersana Therapeutics board · FY2021–FY2024
Director compensation in US dollars, as Mersana Therapeutics reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2024$40,000—$105,996—$145,996
FY2021—————

Each year as the company reported it in Mersana Therapeutics's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Mersana Therapeutics pays directors a $40,000 cash retainer and $105,996 in Options. As stated in Mersana Therapeutics's FY2024 proxy.

The full Mersana Therapeutics compensation record

free company brief

This page is one person within Mersana Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Mersana Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Mersana Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Anna Protopapas's compensation dossier · One-time report. No refunds.